Table 1. Comparison of Treatment... | American Society of Hematology

Table 1.

Comparison of Treatment Histories Based on Either Ig V Gene Mutation Status or the Percentages of CD38⁺ B-CLL Cells

	Unmutated	Mutated
Patients requiring no or minimal^*treatment	20.8% (5/24)	78.3% (18/23)
Patients requiring continuous chemotherapy or chemotherapy with 2 or more agents or regimens	79.2% (19/24)	21.7% (5/23)
	P = .0001^†
	≥30% CD38⁺ B-CLL Cells	<30% CD38⁺ B-CLL Cells
Patients requiring no or minimal^* treatment	23.5% (4/17)	73.7% (14/19)
Patients requiring continuous chemotherapy or chemotherapy with 2 or mor eagents or regimens	76.5% (13/17)	26.3% (5/19)
	P = .0067^†

	Unmutated	Mutated
Patients requiring no or minimal^*treatment	20.8% (5/24)	78.3% (18/23)
Patients requiring continuous chemotherapy or chemotherapy with 2 or more agents or regimens	79.2% (19/24)	21.7% (5/23)
	P = .0001^†
	≥30% CD38⁺ B-CLL Cells	<30% CD38⁺ B-CLL Cells
Patients requiring no or minimal^* treatment	23.5% (4/17)	73.7% (14/19)
Patients requiring continuous chemotherapy or chemotherapy with 2 or mor eagents or regimens	76.5% (13/17)	26.3% (5/19)
	P = .0067^†

Minimal treatment is defined as less than 6 months of therapy in the years of follow-up.

Statistical analyses performed using the 2-tailed Fisher’s exact test.